Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or Qtc > msec
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association functional classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmia, congestive heart failure, any class  or  cardiac disease as defined by the New York Heart Association functional classification, or history of myocardial infarction within  months prior to first dose with study drug
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of first dose of study drug, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) >  msec (calculated using Friderica's formula: QT/RR.) at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, QT prolongation or familial history of QT prolongation, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association functional classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Relapsed/refractory MCL: Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within  months at the time of consent or any class  (moderate) or  (severe) cardiac disease defined by the New York Heart Association classification
Newly diagnosed MCL: Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within  months at the time of consent or any class  (moderate) or  (severe) cardiac disease defined by the New York Heart Association Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within  months at the time of consent or any class  (moderate) or  (severe) cardiac disease defined by the New York Heart Association classification.
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within  months at the time of consent or any class  (moderate) or  (severe) cardiac disease defined by the New York Heart Association classification.
Significant cardiovascular disease such as uncontrolled or symptomatic untreated arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or QTc >  msec at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Significant cardiovascular disease such as uncontrolled or untreated symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification.Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Patient has clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification, left ventricular ejection fraction (LVEF) < % as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO), unstable angina pectoris, symptomatic pericarditis, corrected QT Fridericia's formula (QTcF) >  msec on the screening electrocardiogram (ECG) (using the QTcF formula)
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class III or IV cardiac disease as defined by the New York Heart Association (NYHA) functional classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional classification
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association functional classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of Screening, or any Class  (moderate) or Class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification, or congenital long QT syndrome, or QT interval corrected for heart rate, using Fridericia formula (QTcF) at Screening greater than (>)  milliseconds (ms)
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or corrected QT interval (QTc) >  msec.
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or LVEF < %
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or LVEF > %
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  or  cardiac disease as defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) ? %.
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any Class  (moderate) or Class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association > class ), unstable angina, uncontrolled hypertension, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification would be exclusion for ibrutinib therapy but idelalisib would be an option
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Congestive heart failure > Class II New York Heart Association Functional Classification, current pericarditis, myocardial infarction within  months, or symptomatic coronary artery disease.
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction =<  months prior to registration, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association functional classification
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, (third-degree atrioventricular [AV] block, ventricular tachycardia, atrial fibrillation with rapid ventricular rate [heart rate (HR) >  beats per minute (bpm)]),congestive heart failure, or myocardial infarction within  months of screening, or any class  or  cardiac disease as defined by the New York Heart Association Functional Classification
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening, or any class  (moderate) or class  (severe) cardiac disease as defined by the New York Heart Association Functional Classification
